These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15679171)

  • 21. Role of pharmacologically active metabolites in drug discovery and development.
    Fura A
    Drug Discov Today; 2006 Feb; 11(3-4):133-42. PubMed ID: 16533711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical appraisal of structure-based drug design.
    Tintelnot-Blomley M; Lewis RA
    IDrugs; 2006 Feb; 9(2):114-8. PubMed ID: 16523401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicophores: groups and metabolic routes associated with increased safety risk.
    Williams DP; Naisbitt DJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):104-15. PubMed ID: 11865664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biochemistry of drug metabolism--an introduction: part 1. Principles and overview.
    Testa B; Krämer SD
    Chem Biodivers; 2006 Oct; 3(10):1053-101. PubMed ID: 17193224
    [No Abstract]   [Full Text] [Related]  

  • 27. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
    Dambach DM; Andrews BA; Moulin F
    Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
    Ma S; Subramanian R
    J Mass Spectrom; 2006 Sep; 41(9):1121-39. PubMed ID: 16967439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Unwanted and toxic drug effects].
    Dominok GW; Terhaag B
    Z Arztl Fortbild (Jena); 1984; 78(23):973-6. PubMed ID: 6528640
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of toxic metabolites during drug development.
    Park K; Williams DP; Naisbitt DJ; Kitteringham NR; Pirmohamed M
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):425-34. PubMed ID: 15996699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs in action.
    Eggert US; Superti-Furga G
    Nat Chem Biol; 2008 Jan; 4(1):7-11. PubMed ID: 18084271
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of binding kinetics in therapeutically useful drug action.
    Swinney DC
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):31-9. PubMed ID: 19152211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiosyncratic reactions and metabolism of sulfur-containing drugs.
    Zuniga FI; Loi D; Ling KH; Tang-Liu DD
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):467-85. PubMed ID: 22394356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein-site targeting. Diversification of the drug discovery process.
    Krantz A
    Nat Biotechnol; 1998 Dec; 16(13):1294. PubMed ID: 9853592
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacological and toxicological significance of the stereochemistry of drug disposition.
    Caldwell J; Winter SM; Hutt AJ
    Xenobiotica; 1988 Jan; 18 Suppl 1():59-70. PubMed ID: 3344590
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of metabolic activation in drug toxicity.
    Hinson JA; Pumford NR; Nelson SD
    Drug Metab Rev; 1994; 26(1-2):395-412. PubMed ID: 7521825
    [No Abstract]   [Full Text] [Related]  

  • 40. [METAPRINT: a metabolic fingerprint].
    Keserü GM; Molnár L
    Acta Pharm Hung; 2002; 72(2):92-100. PubMed ID: 12498035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.